The α1-Adrenergic Receptor Antagonist, Prazosin, Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats

被引:71
作者
Rasmussen, Dennis D. [1 ]
Alexander, Laura L. [2 ]
Raskind, Murray A. [1 ]
Froehlich, Janice C. [2 ]
机构
[1] Univ Washington, Seattle, WA 98195 USA
[2] Indiana Univ, Sch Med, Indianapolis, IN USA
关键词
Noradrenergic; Prazosin; Alcohol; Alcohol-Preferring; P Rats; CHRONIC DAILY ETHANOL; POSITIVE REINFORCING PROPERTIES; DOPAMINE-BETA-HYDROXYLASE; ACOUSTIC STARTLE; ANXIETY DISORDERS; NORADRENERGIC MEDIATION; STRIA TERMINALIS; LABORATORY RATS; BED NUCLEUS; WITHDRAWAL;
D O I
10.1111/j.1530-0277.2008.00829.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Preliminary evidence suggest that noradrenergic signaling may play a role in mediating alcohol drinking behavior in both humans and rats. Accordingly, we tested the hypothesis that blockade of alpha(1)-adrenergic receptors will suppress alcohol drinking in rats selectively bred for alcohol preference (P line). Adult male P rats were given 24-hour access to food and water and scheduled access to a 15% (v/v) alcohol solution for 2 hours daily. Rats were injected IP with the alpha(1)-adrenergic receptor antagonist, prazosin (0, 0.5, 1.0, 1.5, or 2.0 mg/kg body weight), once a day at 15 minutes prior to onset of the daily 2-hour 2-bottle choice, alcohol versus water, access period for 2 consecutive days and then 3 weeks later for 5 consecutive days. Prazosin significantly reduced (p < 0.01) alcohol intake during the initial 2 daily administrations, and this reduction of alcohol intake was maintained for 5 consecutive days by daily prazosin treatment in the subsequent more prolonged trial (p < 0.05). The prazosin-induced reduction of alcohol intake was not dependent upon drug-induced motor impairment since increases in water drinking (p < 0.05) were exhibited during the 2-hour access periods during both 2- and 5-day prazosin treatment. The results indicate that the noradrenergic system plays a role in mediating alcohol drinking in rats of the P line and suggest that prazosin-a safe, well-characterized, and well-tolerated drug-may be an effective pharmacotherapeutic agent for the treatment of alcohol use disorders.
引用
收藏
页码:264 / 272
页数:9
相关论文
共 42 条